Medtap: Why Mineralocorticoid Receptor Antagonists In Heart Failure With Reduced Ejection Fraction

MedTap: Why mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction?

Guy's and St Thomas' NHS Foundation Trust

MedTap: Why beta-blockers in heart failure with reduced ejection fraction

Guy's and St Thomas' NHS Foundation Trust

MedTap: Side effects and how to take mineralocorticoid receptor antagonists (MRAs)

Guy's and St Thomas' NHS Foundation Trust

Mineralocorticoid Receptor Antagonists

Duke Clinical Research Institute

Navigating the Landscape of Mineralocorticoid Receptor Antagonists Therapy

Yale Cardiovascular Medicine Grand Rounds

Mineralocorticoid Receptor Blockade and CVD: What's the Story?

Heart failure: Treatment: Aldosterone antagonists

Dr. Andras Fazakas

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)

Neprilysin Inhibition: In Heart Failure and Beyond

Mineralocorticoid Receptor Antagonists: Are They All Created Equal?

Nonsteroidal mineralocorticoid receptor antagonists & cardiorenal outcomes in chronic kidney disease

ERA - European Renal Association

Exploring the Power of Angiotensin-Receptor Blockers (ARBs) in Heart Failure Treatment

Drugs In Chronic Heart Failure - Beta blockers and ARNI

Counterpharmacology

Sodium Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced Ejection Fraction

ATRIUM Collaborative

Targeting Sub-cellular Mechanisms to Treat Heart Failure - Stefanie Dimmeler

Ted Rogers Centre for Heart Research

Heart Failure Nurse Specialist Forum - 21 Sep 2021

South London Cardiovascular Networks

Angiotensin Receptor Aldosterone Antagonist (ARNI)- Latest ESC Guidelines 2021

New Standards for Medical Care of Heart Failure with Reduced Ejection Fraction - Dr. James Januzzi

Mount Sinai Heart Grand Rounds

Webinar 4

Egyptian Society Of Cardiology